403 related articles for article (PubMed ID: 31821784)
21. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract][Full Text] [Related]
22. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
24. MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape.
Olsen SN; Godfrey L; Healy JP; Choi YA; Kai Y; Hatton C; Perner F; Haarer EL; Nabet B; Yuan GC; Armstrong SA
Mol Cell; 2022 Mar; 82(6):1140-1155.e11. PubMed ID: 35245435
[TBL] [Abstract][Full Text] [Related]
25. Targeting the undruggable: menin inhibitors ante portas.
Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
[TBL] [Abstract][Full Text] [Related]
26. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
[TBL] [Abstract][Full Text] [Related]
27. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
28. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
29. Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
Libbrecht C; Xie HM; Kingsley MC; Haladyna JN; Riedel SS; Alikarami F; Lenard A; McGeehan GM; Ernst P; Bernt KM
Leukemia; 2021 May; 35(5):1405-1417. PubMed ID: 33542482
[TBL] [Abstract][Full Text] [Related]
30. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
[TBL] [Abstract][Full Text] [Related]
31. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
32. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung M; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ
Oncogene; 2019 May; 38(20):3824-3842. PubMed ID: 30670779
[TBL] [Abstract][Full Text] [Related]
33. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
[TBL] [Abstract][Full Text] [Related]
34. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
[TBL] [Abstract][Full Text] [Related]
35. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
36. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
[TBL] [Abstract][Full Text] [Related]
37. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
[TBL] [Abstract][Full Text] [Related]
38. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
39. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
[TBL] [Abstract][Full Text] [Related]
40. SON and Its Alternatively Spliced Isoforms Control MLL Complex-Mediated H3K4me3 and Transcription of Leukemia-Associated Genes.
Kim JH; Baddoo MC; Park EY; Stone JK; Park H; Butler TW; Huang G; Yan X; Pauli-Behn F; Myers RM; Tan M; Flemington EK; Lim ST; Ahn EY
Mol Cell; 2016 Mar; 61(6):859-73. PubMed ID: 26990989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]